Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387242034> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4387242034 abstract "In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events. However, whether this early short-course corticosteroid use prevents immune-related adverse events (irAEs) remains unknown.Between January 1st 2015 and December 31st 2020, NSCLC patients who received at least one cycle of ICI with or without chemotherapy were enrolled. Early short-course corticosteroids were defined as corticosteroids administered following ICI injection and before chemotherapy on the same day and no longer than 3 days afterwards. The patients were categorized as either corticosteroid group or non-corticosteroid group depending on their exposure to corticosteroid premedication. The frequencies of irAEs requiring systemic corticosteroid use and irAEs leading to ICI discontinuation were compared between the two groups, and exploratory survival analyses were performed.Among 252 eligible patients, 137 patients were categorized as corticosteroid group, and 115 patients as non-corticosteroid group. The corticosteroid group enriched patients in the first-line setting (n = 75, 54.7%), compared to the non-corticosteroid group (n = 28, 24.3%). Thirty patients (21.9%) in the corticosteroid group and 35 patients (30.4%) in the non-corticosteroid group developed irAEs requiring systemic corticosteroid use (Odds ratio [OR], 0.64; 95% confidence interval [CI], 0.35 to 1.18; p = 0.15). Eight patients (5.8%) in the corticosteroid group, as compared with 18 patients (15.7%) in the non-corticosteroid group, permanently discontinued ICI due to irAEs (OR, 0.34; 95% CI, 0.12 to 0.85; p = 0.013).Early short-course corticosteroids following each ICI injection may reduce the rate of irAEs that leads to ICIs discontinuation, warranting further investigation of its prophylactic use to mitigate clinically significant irAEs." @default.
- W4387242034 created "2023-10-03" @default.
- W4387242034 creator A5004428301 @default.
- W4387242034 creator A5004699298 @default.
- W4387242034 creator A5004892116 @default.
- W4387242034 creator A5009000893 @default.
- W4387242034 creator A5013389671 @default.
- W4387242034 creator A5014523023 @default.
- W4387242034 creator A5033582283 @default.
- W4387242034 creator A5036843957 @default.
- W4387242034 creator A5048965137 @default.
- W4387242034 creator A5055074037 @default.
- W4387242034 creator A5055415475 @default.
- W4387242034 creator A5056367345 @default.
- W4387242034 creator A5084397879 @default.
- W4387242034 creator A5086650300 @default.
- W4387242034 creator A5087678313 @default.
- W4387242034 date "2023-09-29" @default.
- W4387242034 modified "2023-10-17" @default.
- W4387242034 title "Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors." @default.
- W4387242034 doi "https://doi.org/10.1159/000534350" @default.
- W4387242034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37778345" @default.
- W4387242034 hasPublicationYear "2023" @default.
- W4387242034 type Work @default.
- W4387242034 citedByCount "0" @default.
- W4387242034 crossrefType "journal-article" @default.
- W4387242034 hasAuthorship W4387242034A5004428301 @default.
- W4387242034 hasAuthorship W4387242034A5004699298 @default.
- W4387242034 hasAuthorship W4387242034A5004892116 @default.
- W4387242034 hasAuthorship W4387242034A5009000893 @default.
- W4387242034 hasAuthorship W4387242034A5013389671 @default.
- W4387242034 hasAuthorship W4387242034A5014523023 @default.
- W4387242034 hasAuthorship W4387242034A5033582283 @default.
- W4387242034 hasAuthorship W4387242034A5036843957 @default.
- W4387242034 hasAuthorship W4387242034A5048965137 @default.
- W4387242034 hasAuthorship W4387242034A5055074037 @default.
- W4387242034 hasAuthorship W4387242034A5055415475 @default.
- W4387242034 hasAuthorship W4387242034A5056367345 @default.
- W4387242034 hasAuthorship W4387242034A5084397879 @default.
- W4387242034 hasAuthorship W4387242034A5086650300 @default.
- W4387242034 hasAuthorship W4387242034A5087678313 @default.
- W4387242034 hasConcept C126322002 @default.
- W4387242034 hasConcept C156957248 @default.
- W4387242034 hasConcept C197934379 @default.
- W4387242034 hasConcept C2776256026 @default.
- W4387242034 hasConcept C2776694085 @default.
- W4387242034 hasConcept C2776804153 @default.
- W4387242034 hasConcept C2778715236 @default.
- W4387242034 hasConcept C71924100 @default.
- W4387242034 hasConceptScore W4387242034C126322002 @default.
- W4387242034 hasConceptScore W4387242034C156957248 @default.
- W4387242034 hasConceptScore W4387242034C197934379 @default.
- W4387242034 hasConceptScore W4387242034C2776256026 @default.
- W4387242034 hasConceptScore W4387242034C2776694085 @default.
- W4387242034 hasConceptScore W4387242034C2776804153 @default.
- W4387242034 hasConceptScore W4387242034C2778715236 @default.
- W4387242034 hasConceptScore W4387242034C71924100 @default.
- W4387242034 hasLocation W43872420341 @default.
- W4387242034 hasOpenAccess W4387242034 @default.
- W4387242034 hasPrimaryLocation W43872420341 @default.
- W4387242034 hasRelatedWork W1967103478 @default.
- W4387242034 hasRelatedWork W2032912323 @default.
- W4387242034 hasRelatedWork W2063006222 @default.
- W4387242034 hasRelatedWork W2340298857 @default.
- W4387242034 hasRelatedWork W2372561159 @default.
- W4387242034 hasRelatedWork W2375344515 @default.
- W4387242034 hasRelatedWork W2390152934 @default.
- W4387242034 hasRelatedWork W2466043692 @default.
- W4387242034 hasRelatedWork W2468137916 @default.
- W4387242034 hasRelatedWork W4386640344 @default.
- W4387242034 isParatext "false" @default.
- W4387242034 isRetracted "false" @default.
- W4387242034 workType "article" @default.